Altimmune, Inc. Common Stock
ALT Real Time Price USDRecent trades of ALT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ALT's directors and management
Government lobbying spending instances
-
$80,000 Jul 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Manufacturing Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$80,000 Apr 20, 2021 Issue: Health Issues
-
$40,000 Apr 20, 2021 Issue: Manufacturing Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$90,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: Medical/Disease Research/Clinical Labs Manufacturing Health Issues Budget/Appropriations
-
$80,000 Oct 20, 2020 Issue: Health Issues
-
$40,000 Oct 20, 2020 Issue: Budget/Appropriations Manufacturing Health Issues Medical/Disease Research/Clinical Labs
-
$5,000 Jul 20, 2020 Issue: Health Issues
-
$20,000 Jul 20, 2020 Issue: Manufacturing Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$30,000 Apr 20, 2020 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Peptide pharmaceuticals for treatment of nash and other disorders Jan. 03, 2023
-
Patent Title: Coronavirus immunogenic compositions and uses thereof Jul. 12, 2022
-
Patent Title: Rapid and prolonged immunologic-therapeutic Oct. 12, 2021
-
Patent Title: Rapid and prolonged immunogic therapeutic Jun. 22, 2021
-
Patent Title: Rapid and prolonged immunologic therapeutic Jun. 22, 2021
-
Patent Title: Immunization of avians by administration of non-replicating vectored vaccines Aug. 18, 2020
-
Patent Title: Rapid and prolonged immunologic-therapeutic Jan. 22, 2019
-
Patent Title: Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax May. 15, 2018
-
Patent Title: Rapid and prolonged immunologic-therapeutic Mar. 28, 2017
-
Patent Title: Rapid and prolonged immunologic-therapeutic Nov. 03, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ALT in WallStreetBets Daily Discussion
Recent insights relating to ALT
Recent picks made for ALT stock on CNBC
ETFs with the largest estimated holdings in ALT
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.